微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 35.03% | 1.44% | 0.91% | 103/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 34.72% | -2.05% | 1.77% | 107/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 34.11% | -10.67% | -11.93% | 106/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 38.73% | -4.77% | 12.17% | 105/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 34.53% | -15.64% | -2.57% | 110/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 35.44% | -17.5% | -7.19% | 107/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 38.19% | -13.11% | -6.12% | 100/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 40.68% | 4.42% | -0.64% | 103/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 40.94% | 5.92% | -4.71% | 101/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 42.96% | 11.19% | -2.25% | 98/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 43.95% | 13.15% | 12.82% | 93/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 38.96% | -1.34% | 0.8% | 104/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 38.65% | -1.27% | 0.03% | 101/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 38.64% | -3.34% | -0.53% | 104/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 38.84% | -4.84% | -1.63% | 98/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 39.49% | 0.83% | 0.87% | 107/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 39.15% | -3.67% | -2.06% | 96/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 39.97% | -4.63% | -2.07% | 101/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 40.82% | -2.7% | 4.23% | 84/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 39.16% | -10.14% | -3.63% | 107/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 40.64% | -7.44% | -3.04% | 89/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 41.91% | -6.3% | -0.1% | 91/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 41.95% | -7.49% | -3.73% | 79/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 43.58% | 5.32% | -0.74% | 89/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 43.9% | 7.05% | -1.85% | 71/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 44.73% | 6.13% | -1.37% | 72/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 45.35% | 11.93% | 9.6% | 66/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 41.38% | 4.64% | 0.89% | 91/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 41.01% | 14.56% | -2.69% | 70/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 42.14% | 20.32% | 4.02% | 69/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 40.51% | 20.03% | 2.46% | 72/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 39.54% | 25.3% | 10.45% | 78/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 35.8% | 16.5% | 2.21% | 69/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 35.03% | 10.74% | 3.77% | 74/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 33.75% | 5.37% | 6.96% | 60/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 31.56% | 18.95% | 2.7% | 88/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 30.73% | 8.86% | -2.85% | 61/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 31.63% | 9.94% | -1.26% | 67/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 32.03% | 15.05% | 20.74% | 55/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 26.53% | -15.85% | -6.01% | 86/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 28.23% | -14.02% | -1.88% | 59/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 28.77% | -14.13% | 3.33% | 59/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 27.84% | -7.66% | -11.69% | 53/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |